A registration-directed randomised clinical trial of selinexor [KPT 330] in patients with diffuse large B-cell lymphoma

Trial Profile

A registration-directed randomised clinical trial of selinexor [KPT 330] in patients with diffuse large B-cell lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs Selinexor (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Nov 2014 Planned initiation date changed from 1 Aug 2014 to 1 Dec 2014, according to a Karyopharm Therapeutics media release.
    • 07 May 2014 Trial initiation is expected in the second half of 2014, according to a Karyopharm Therapeutics media release.
    • 10 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top